Pinnbrook Capital Management LP Acquires Shares of 154,740 Ralliant Corporation $RAL

Pinnbrook Capital Management LP acquired a new stake in Ralliant Corporation (NYSE:RAL) in the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 154,740 shares of the company’s stock, valued at approximately $7,878,000. Ralliant makes up 1.1% of Pinnbrook Capital Management LP’s holdings, making the stock its 26th largest position.

Other large investors also recently added to or reduced their stakes in the company. Danske Bank A S purchased a new stake in Ralliant in the 4th quarter valued at about $25,000. Allworth Financial LP boosted its position in Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after buying an additional 293 shares during the period. V Square Quantitative Management LLC purchased a new stake in Ralliant in the 4th quarter valued at about $26,000. Westfuller Advisors LLC purchased a new stake in Ralliant in the 3rd quarter valued at about $26,000. Finally, Palisade Asset Management LLC purchased a new stake in Ralliant in the 3rd quarter valued at about $26,000.

Ralliant Trading Up 0.4%

NYSE:RAL opened at $59.92 on Friday. Ralliant Corporation has a one year low of $37.27 and a one year high of $62.35. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. The firm has a market cap of $6.71 billion and a P/E ratio of -5.48. The firm has a 50-day simple moving average of $46.55 and a 200-day simple moving average of $47.99.

Ralliant (NYSE:RAL) last posted its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.49 by $0.08. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The business had revenue of $534.60 million during the quarter. The business’s quarterly revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Equities analysts anticipate that Ralliant Corporation will post 2.63 EPS for the current fiscal year.

Ralliant Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th will be issued a $0.05 dividend. The ex-dividend date is Monday, June 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Ralliant’s payout ratio is currently -1.83%.

Analyst Ratings Changes

RAL has been the subject of several research reports. Weiss Ratings reissued a “sell (d)” rating on shares of Ralliant in a research report on Monday, May 4th. Vertical Research raised shares of Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price objective for the company in a research report on Friday, February 6th. Morgan Stanley boosted their price objective on shares of Ralliant from $45.00 to $68.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. TD Cowen boosted their price objective on shares of Ralliant from $55.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Oppenheimer boosted their price target on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, May 13th. Seven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $62.50.

Insider Activity at Ralliant

In other news, SVP Karen M. Bick sold 2,530 shares of the business’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $46.50, for a total value of $117,645.00. Following the completion of the sale, the senior vice president owned 42,652 shares in the company, valued at approximately $1,983,318. The trade was a 5.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.